LOGC:NSD-Contextlogic Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 5.43

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.16M

Analyst Target

USD 22.00
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

-11.11 (-0.95%)

USD 130.01B
VRTX Vertex Pharmaceuticals Inc

+6.72 (+1.40%)

USD 123.52B
ALNY Alnylam Pharmaceuticals Inc

+3.54 (+1.35%)

USD 33.60B
ARGX argenx NV ADR

+2.24 (+0.42%)

USD 32.41B
MRNA Moderna Inc

-1.40 (-2.01%)

USD 28.23B
BGNE BeiGene Ltd

+2.22 (+1.13%)

USD 20.54B
BMRN Biomarin Pharmaceutical Inc

+0.52 (+0.62%)

USD 17.44B
RPRX Royalty Pharma Plc

+0.17 (+0.62%)

USD 17.14B
UTHR United Therapeutics Corporatio..

-1.99 (-0.58%)

USD 15.72B
PCVX Vaxcyte Inc

+1.87 (+1.64%)

USD 14.27B

ETFs Containing LOGC

INKM SPDR® SSgA Income Alloca.. 16.71 % 0.39 %

+0.21 (+0.34%)

USD 0.08B
FISR SPDR® SSGA Fixed Income .. 15.47 % 0.00 %

+0.09 (+0.34%)

USD 0.34B
GAL SPDR® SSgA Global Alloca.. 2.55 % 0.09 %

+0.20 (+0.34%)

USD 0.24B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 162.32% 95% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 162.32% 95% A 97% N/A
Trailing 5 Years  
Capital Gain -26.62% 61% D- 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.62% 61% D- 32% F
Average Annual (5 Year Horizon)  
Capital Gain 43.93% 84% B 89% A-
Dividend Return 43.93% 84% B 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 162.61% 19% F 10% F
Risk Adjusted Return 27.02% 82% B 60% D-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.